Loading...
Market
GSK Drug Exceeds £3 Billion in First-Year Sales?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
GSK's annual financial reports or official press releases
Story
GSK's Experimental Asthma Drug Shows Promise in Late-Stage Trials, Potential £3 Billion Sales
May 21, 2024, 07:01 AM
An experimental drug from GlaxoSmithKline (GSK) has shown promising results in reducing severe asthma attacks in late-stage trials. The British pharmaceutical company announced on Tuesday that the drug met its primary goal of reducing asthma attacks over a 52-week period in a key trial. The success of these trials paves the way for a treatment that GSK believes could exceed £3 billion in sales, potentially making it a blockbuster product.
View original story
Similar markets
Below £500 million • 25%
£500 million to £1 billion • 25%
£1 billion to £2 billion • 25%
Above £2 billion • 25%
Increase • 33%
No significant change • 33%
Decrease • 33%
Below $1 billion • 33%
$1 billion - $5 billion • 33%
Above $5 billion • 34%
Less than $1 billion • 33%
$1 billion to $5 billion • 33%
More than $5 billion • 33%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
